Dalteparin sodium for the prevention of venous thromboembolism in advanced pancreatic cancer patients undergoing chemotherapy
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2013
Price : $35 *
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 10 Dec 2013 Results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
- 10 Dec 2013 New trial record
- 09 Dec 2013 Primary endpoint 'Disease-occurrence-rate' has been met.